Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity

Patent metadata

Field	Value
Publication number	US-10865234-B2
Application number	US-201916513859-A
Country	US
Kind code	B2
Filing date	Jul 17, 2019
Priority date	Mar 17, 2009
Publication date	Dec 15, 2020
Grant date	Dec 15, 2020

Abstract

The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.

First claim

What is claimed is:

1. A pharmaceutical composition comprising
a non-naturally occurring anti-HIV-I PG9 monoclonal antibody or antigen binding portion thereof comprising:
(a) a light chain variable region comprising three complementarity determining regions comprising the amino acid sequences of SEQ ID NOS: 126, 127, and 45; and
(b) a heavy chain variable region comprising three complementarity determining regions comprising the amino acid sequences of SEQ ID NOS: 123, 124; and 7; and
a pharmaceutically acceptable carrier,
wherein the carrier is selected from the group consisting of a buffer, organic acid, antioxidant, preservative, alkyl paraben, oligopeptide, protein, amino acid, hydrophilic polymer, carbohydrate, chelating agent, tonicifier, sugar, and surfactant.

2. The composition of claim 1 , wherein the antibody comprises:
(a) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 40; and
(b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 39.

3. The composition of claim 1 , wherein the antibody comprises:
(a) a light chain sequence comprising the amino acid sequence of SEQ ID NO: 30; and
(b) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 28.

4. A pharmaceutical composition comprising
a non-naturally occurring anti-HIV-1 PG16 monoclonal antibody or antigen binding portion thereof comprising:
(a) a light chain variable region comprising three complementarity determining regions comprising the amino acid sequences of SEQ ID NOS: 92, 95, and 41, or SEQ ID NOS: 93, 95, and 41, or SEQ ID NOS: 97, 95, and 41; and
(b) a heavy chain variable region comprising three complementarity determining regions comprising the amino acid sequences of SEQ ID NOS: 88, 89, and 6, or SEQ ID NOS: 88, 98, and 6; and
a pharmaceutically acceptable carrier,
wherein the carrier is selected from the group consisting of a buffer, organic acid, antioxidant, preservative, alkyl paraben, oligopeptide, protein, amino acid, hydrophilic polymer, carbohydrate, chelating agent, tonicifier, sugar, and surfactant.

5. The composition of claim 4 , wherein the antibody comprises:
(a) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 32 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 31; or
(b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 96 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 140; or
(c) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 51 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 48; or
(d) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 57 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 54; or
(e) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 32 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 60; or
(f) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 32 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 31.

6. The composition of claim 4 , wherein the antibody comprises:
(a) a light chain sequence comprising the amino acid sequence of SEQ ID NO: 14 and a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 12; or
(b) a light chain sequence comprising the amino acid sequence of SEQ ID NO: 142 and a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 139; or
(c) a light chain sequence comprising the amino acid sequence of SEQ ID NO: 50 and a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 47; or
(d) a light chain sequence comprising the amino acid sequence of SEQ ID NO: 56 and a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 53; or
(e) a light chain sequence comprising the amino acid sequence of SEQ ID NO: 14 and a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 59; or
(f) a light chain sequence comprising the amino acid sequence of SEQ ID NO: 14 and a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 65.

7. The composition according to claim 1 or 4 , wherein the buffer is acetate, Tris, phosphate, or citrate.

Assignees

• Theraclone Sciences Inc
• Int Aids Vaccine Initiative
• Scripps Research Inst

Inventors

• Chan-Hui Po-Ying
• Frey Steven
• Olsen Ole
• Mitcham Jennifer
• Moyle Matthew
• Phogat Sanjay K
• Burton Dennis R
• Walker Laura Marjorie
• Poignard Pascal Raymond Georges
• Koff Wayne
• Simek-Lemos Melissa Danielle De Jean De St Marcel
• Kaminsky Stephen

Classifications

• C07K16/1145

  Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title

• C07K16/114 Primary

  Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV] · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• A61P31/14

  for RNA viruses · CPC title